⌕
Mirum Pharmaceuticals · MIRM · Nasdaq
Tenet 42 · Weak
Compare
$93.99+0.71%At closeTenet 42 · Weak
$93.99+0.66 (+0.71%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Mirum Pharmaceuticals (MIRM) Stock

Mirum Pharmaceuticals (MIRM) closed at $93.99 on Nov 13, 2026; its Tenet Score is 42 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

28 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$93.99
Nov 13, 2026
Market cap
$6.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
63.23 – 130.00
low → high · as of close, Nov 13, 2026
Tenet Score
42/100
Weak · 297 Healthcare peers

Industry: Health Services

Mirum Pharmaceuticals Inc scores 42/100. Weak. Quality is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 42 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=297
42/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
32
Health
39
Growth
56

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityDHealthDGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
9.1×
price to fiscal 2025 sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−4.2%
fiscal 2025, before interest and tax
Net margin
−134.8%
of revenue kept
Current ratio
2.07
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the t…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 88 US ETFs · top wrappers by weightSee all ETFs holding MIRM →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Mirum Pharmaceuticals in?

Mirum Pharmaceuticals is in the Healthcare sector and the Health Services industry.

What is Mirum Pharmaceuticals' Tenet Score?

Mirum Pharmaceuticals' Tenet Score is 42 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.